Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

PR Newswire December 7, 2023

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

PR Newswire December 4, 2023

Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences

PR Newswire November 9, 2023

Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results

PR Newswire November 8, 2023

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

PR Newswire November 1, 2023

Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

PR Newswire October 20, 2023

Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

PR Newswire October 5, 2023

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

PR Newswire September 6, 2023

Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

PR Newswire July 27, 2023

Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

PR Newswire July 20, 2023

Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference

PR Newswire June 5, 2023

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

PR Newswire June 1, 2023

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

PR Newswire June 1, 2023

Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

PR Newswire May 25, 2023

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

PR Newswire May 10, 2023

Vanda Pharmaceuticals Announces Presentations at DDW 2023

PR Newswire May 4, 2023

Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

PR Newswire May 3, 2023

Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

PR Newswire May 2, 2023

Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023

PR Newswire April 27, 2023

Vanda Prevails in Jet Lag Litigation Against the FDA

PR Newswire March 28, 2023